Advances in biomaterial-based cardiac organoids.


Journal

Biomaterials advances
ISSN: 2772-9508
Titre abrégé: Biomater Adv
Pays: Netherlands
ID NLM: 9918383886206676

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 16 02 2023
revised: 27 05 2023
accepted: 05 06 2023
medline: 1 9 2023
pubmed: 23 6 2023
entrez: 23 6 2023
Statut: ppublish

Résumé

Cardiovascular disease (CVD) is one of the important causes of death worldwide. The incidence and mortality rates are increasing annually with the intensification of social aging. The efficacy of drug therapy is limited in individuals suffering from severe heart failure due to the inability of myocardial cells to undergo regeneration and the challenging nature of cardiac tissue repair following injury. Consequently, surgical transplantation stands as the most efficient approach for treatment. Nevertheless, the shortage of donors and the considerable number of heart failure patients worldwide, estimated at 26 million, results in an alarming treatment deficit, with only around 5000 heart transplants feasible annually. The existing major alternatives, such as mechanical or xenogeneic hearts, have significant flaws, such as high cost and rejection, and are challenging to implement for large-scale, long-term use. An organoid is a three-dimensional (3D) cell tissue that mimics the characteristics of an organ. The critical application has been rated in annual biotechnology by authoritative journals, such as Science and Cell. Related industries have achieved rapid growth in recent years. Based on this technology, cardiac organoids are expected to pave the way for viable heart repair and treatment and play an essential role in pathological research, drug screening, and other areas. This review centers on the examination of biomaterials employed in cardiac repair, strategies employed for the reconstruction of cardiac structure and function, clinical investigations pertaining to cardiac repair, and the prospective applications of cardiac organoids. From basic research to clinical practice, the current status, latest progress, challenges, and prospects of biomaterial-based cardiac repair are summarized and discussed, providing a reference for future exploration and development of cardiac regeneration strategies.

Identifiants

pubmed: 37352743
pii: S2772-9508(23)00225-X
doi: 10.1016/j.bioadv.2023.213502
pii:
doi:

Substances chimiques

Biocompatible Materials 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

213502

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Caixia Fan (C)

School of Life and Environmental Sciences, Shaoxing University, Shaoxing 312000, Zhejiang, China. Electronic address: 2022000051@usx.edu.cn.

Jiaxiong He (J)

School of Life and Environmental Sciences, Shaoxing University, Shaoxing 312000, Zhejiang, China. Electronic address: 3124814650@qq.com.

Sijia Xu (S)

School of Life and Environmental Sciences, Shaoxing University, Shaoxing 312000, Zhejiang, China.

Junyan Yan (J)

School of Life and Environmental Sciences, Shaoxing University, Shaoxing 312000, Zhejiang, China. Electronic address: yyan2018@usx.edu.cn.

Lifang Jin (L)

School of Life and Environmental Sciences, Shaoxing University, Shaoxing 312000, Zhejiang, China. Electronic address: lifangj@usx.edu.cn.

Jianwu Dai (J)

State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100080, China. Electronic address: jwdai@genetics.ac.cn.

Baowei Hu (B)

School of Life and Environmental Sciences, Shaoxing University, Shaoxing 312000, Zhejiang, China. Electronic address: hbw@usx.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH